Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · Melanotan ISupported
Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.
This real-world cohort of 20 patients reports large improvements in quality of life and pain-free light tolerance with afamelanotide, alongside reductions in phototoxic reactions and only mild transient side effects. As an uncontrolled observational study it supports rather than proves benefit, but it aligns with prior clinical-trial findings for this approved orphan indication. Note this is the regulated pharmaceutical form of melanotan-1, distinct from unregulated tanning use.
Journal der Deutschen Dermatologischen Gesellschaftn=—HumanMar 6, 2026 - Study · Melanotan IIWeak / none
Insights into Tanning Biology and Tanning Products.
This PRISMA-guided review of 68 studies covers several tanning agents, with melanotan among the dominant ones discussed. It catalogs serious adverse effects associated with unregulated melanotan use and notes limited long-term safety data across the literature. A useful safety-oriented reference for the melanotan risk profile.
The Journal of clinical and aesthetic dermatologyn=——Feb 1, 2026 - Study · Melanotan IWeak / none
Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases.
Bremelanotide is named here only as an example of an FDA-approved melanocortin-receptor agonist; the review's real subject is how genetic variation in melanocortin receptors (MC1R-MC5R) relates to inflammatory and other disease risk. It offers useful mechanistic context — bremelanotide acts on the same receptor family (chiefly MC3R/MC4R centrally, with MC1R activity explaining the skin-pigmentation effect seen in some trials) that also participates in immune regulation — but it presents no efficacy or safety data for the peptide and does not study it. The inflammatory-disease connections the authors draw (for atopic dermatitis, scleroderma, and others) largely concern other melanocortin ligands such as alpha-MSH analogs, dersimelagon, and afamelanotide, not bremelanotide. Read this as background on the biology of the receptor system bremelanotide targets, and as a reminder that melanocortin signalling is pleiotropic. It contributes nothing to how one should weight the peptide's approved indication.
Diseases (Basel, Switzerland)n=——Sep 16, 2025 - Study · Melanotan IIWeak / none
A single-centre, prospective, qualitative analysis of knowledge, attitudes and behaviour of sunbed use among patients attending a pigmented lesion clinic.
This qualitative survey of sunbed users documents concurrent use of unregulated Melanotan I and II among tanning-focused patients and flags associated public-health risks such as blood-borne infection from injectable use. The peptides are examined as part of tanning behavior rather than for physiological effect. It offers useful real-world context on unregulated melanotan use.
Skin health and diseasen=——Jun 1, 2025 - Study · Melanotan ISupported
German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP).
This is a substantial real-world post-authorisation safety study of afamelanotide (mapped here to melanotan-1) in 200 EPP patients, reporting significant quality-of-life gains and a safety profile consistent with clinical trials. As an observational cohort without a randomized control it cannot isolate treatment effect as cleanly as an RCT, but it is a large, directly relevant dataset on the approved peptide. Findings are framed as association within its regulatory indication.
Photodermatology, photoimmunology & photomedicinen=—HumanMar 1, 2025